Long-acting GLP-1R agonists, liraglutide, semaglutide and dulaglutide have been marketed for the treatment of type 2 diabetes and have been shown to also provide cardiovascular risk reduction (Gerstein et al. 2019; Marso et al. 2016; Davies et al. 2017), while liraglutide is approved for the treatment of obesity (Pi-Sunyer et al. 2015). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.